PPARα can reduce obesity‐induced hepatitis through reducing fatty liver (which is closely related to elevated inflammatory states), by directly regulating the expression of inflammatory genes or by inhibiting inflammation of AT,133 and plays a substantial role during the progression of obesity complicated with NAFLD. The gene discussed is PPARA; the disease is obesity disorder.